• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏瓣膜病中药物干预的病理生理学基础。

The pathophysiological basis of pharmacological interventions in CAVD.

机构信息

Department of Cardiothoracic Surgery, University Medical Center Utrecht, PO BOX 85500, E03.511, 3508GA, Utrecht, the Netherlands,

出版信息

Neth Heart J. 2012 Jun;20(6):270-8. doi: 10.1007/s12471-011-0230-1.

DOI:10.1007/s12471-011-0230-1
PMID:22160992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3370094/
Abstract

Calcific aortic valve disease (CAVD) results in aortic valve stenosis and is one of the most common cardiac diseases in both Western and developing countries. The burden of this disease is expected to increase rapidly in the future, but there are still no relevant pharmacological therapies available and aortic valve replacement remains the sole definite therapy. This review presents an overview of the most common causes of CAVD, followed by current debates and trials related to the onset and progression of this disease. Several differences and similarities between the different causes of CAVD are presented. Additionally, stages of CAVD are compared with stages in atherosclerosis. Finally, future directions for research on CAVD will be discussed.

摘要

钙化性主动脉瓣疾病(CAVD)可导致主动脉瓣狭窄,是西方国家和发展中国家最常见的心脏疾病之一。预计未来这种疾病的负担将迅速增加,但目前仍没有相关的药物治疗方法,主动脉瓣置换仍然是唯一明确的治疗方法。本综述概述了 CAVD 的最常见病因,随后介绍了与这种疾病的发生和进展相关的当前争议和试验。介绍了 CAVD 不同病因之间的一些差异和相似之处。此外,还比较了 CAVD 分期与动脉粥样硬化分期。最后,将讨论 CAVD 研究的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/02cce9d44672/12471_2011_230_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/3a4856fd883f/12471_2011_230_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/41f0d3e16e7d/12471_2011_230_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/72b63ab74cb0/12471_2011_230_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/49fd307b8eec/12471_2011_230_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/02cce9d44672/12471_2011_230_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/3a4856fd883f/12471_2011_230_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/41f0d3e16e7d/12471_2011_230_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/72b63ab74cb0/12471_2011_230_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/49fd307b8eec/12471_2011_230_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/3370094/02cce9d44672/12471_2011_230_Fig5_HTML.jpg

相似文献

1
The pathophysiological basis of pharmacological interventions in CAVD.心脏瓣膜病中药物干预的病理生理学基础。
Neth Heart J. 2012 Jun;20(6):270-8. doi: 10.1007/s12471-011-0230-1.
2
Insights into the use of biomarkers in calcific aortic valve disease.钙化性主动脉瓣疾病中生物标志物的应用见解
J Heart Valve Dis. 2010 Jul;19(4):441-52.
3
In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.体外3D模型与用于靶向钙化性主动脉瓣疾病的miRNA药物递送
Clin Sci (Lond). 2017 Feb 1;131(3):181-195. doi: 10.1042/CS20160378.
4
Label-Free Multiphoton Microscopy for the Detection and Monitoring of Calcific Aortic Valve Disease.用于检测和监测钙化性主动脉瓣疾病的无标记多光子显微镜技术
Front Cardiovasc Med. 2021 Jun 11;8:688513. doi: 10.3389/fcvm.2021.688513. eCollection 2021.
5
Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies.钙化性主动脉瓣狭窄的见解:疾病综述与治疗策略进展
Ann Med Surg (Lond). 2024 Apr 29;86(6):3577-3590. doi: 10.1097/MS9.0000000000002106. eCollection 2024 Jun.
6
Aortic stenosis: a general overview of clinical, pathophysiological and therapeutic aspects.主动脉瓣狭窄:临床、病理生理及治疗方面的概述
Expert Rev Cardiovasc Ther. 2013 Feb;11(2):239-50. doi: 10.1586/erc.12.171.
7
Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments.钙化性主动脉瓣疾病的新型药理学靶点:预防和治疗。
Pharmacol Res. 2018 Oct;136:74-82. doi: 10.1016/j.phrs.2018.08.020. Epub 2018 Aug 24.
8
Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies.钙化性主动脉瓣疾病——自然病史与未来治疗策略
Front Pharmacol. 2020 May 13;11:685. doi: 10.3389/fphar.2020.00685. eCollection 2020.
9
Targeting vasoactive peptides for managing calcific aortic valve disease.以血管活性肽为靶点治疗钙化性主动脉瓣疾病。
Ann Med. 2017 Feb;49(1):63-74. doi: 10.1080/07853890.2016.1231933. Epub 2016 Nov 3.
10
COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification.COX-2 在人狭窄主动脉瓣中下调,其抑制促进退行性钙化。
Int J Mol Sci. 2020 Nov 24;21(23):8917. doi: 10.3390/ijms21238917.

引用本文的文献

1
A calcified sinutubular junction: the discovery of a supravalvular aortic stenosis in an elderly woman.钙化性窦管交界处:老年女性瓣上型主动脉瓣狭窄的发现。
Neth Heart J. 2013 Dec;21(12):561-4. doi: 10.1007/s12471-013-0426-7.

本文引用的文献

1
Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification.分子影像学对动脉和主动脉瓣钙化的早期炎症阶段的研究进展。
Circ Res. 2011 May 27;108(11):1381-91. doi: 10.1161/CIRCRESAHA.110.234146.
2
Aortic valve disease and treatment: the need for naturally engineered solutions.主动脉瓣疾病与治疗:对天然工程解决方案的需求。
Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):242-68. doi: 10.1016/j.addr.2011.01.008. Epub 2011 Jan 31.
3
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
MicroRNA-199b 通过自动扩增环靶向核激酶 Dyrk1a,促进钙调磷酸酶/NFAT 信号传导。
Nat Cell Biol. 2010 Dec;12(12):1220-7. doi: 10.1038/ncb2126. Epub 2010 Nov 21.
4
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).双膦酸盐的使用与女性 MESA(动脉粥样硬化多民族研究)中瓣膜和血管钙化的流行。
J Am Coll Cardiol. 2010 Nov 16;56(21):1752-9. doi: 10.1016/j.jacc.2010.05.050.
5
Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves.二叶式主动脉瓣中微小RNA的改变:狭窄瓣膜与反流瓣膜的比较
J Heart Valve Dis. 2010 Jul;19(4):459-65.
6
Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation.动脉和主动脉瓣钙化与骨质疏松性骨重塑呈负相关:炎症的作用。
Eur Heart J. 2010 Aug;31(16):1975-84. doi: 10.1093/eurheartj/ehq237. Epub 2010 Jul 2.
7
Bicuspid aortic valve disease.二叶式主动脉瓣病变。
J Am Coll Cardiol. 2010 Jun 22;55(25):2789-800. doi: 10.1016/j.jacc.2009.12.068.
8
Biomechanical implications of the congenital bicuspid aortic valve: a finite element study of aortic root function from in vivo data.先天性二叶式主动脉瓣的生物力学意义:基于体内数据的主动脉根部功能有限元研究。
J Thorac Cardiovasc Surg. 2010 Oct;140(4):890-6, 896.e1-2. doi: 10.1016/j.jtcvs.2010.01.016. Epub 2010 Apr 3.
9
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.瑞舒伐他汀降脂治疗对主动脉瓣狭窄进展的影响:主动脉瓣狭窄进展观察研究的结果:评价瑞舒伐他汀的效果(ASTROMER)试验。
Circulation. 2010 Jan 19;121(2):306-14. doi: 10.1161/CIRCULATIONAHA.109.900027. Epub 2010 Jan 4.
10
Osteoporosis treatment and progression of aortic stenosis.骨质疏松症治疗与主动脉瓣狭窄的进展
Am J Cardiol. 2009 Jul 1;104(1):122-4. doi: 10.1016/j.amjcard.2009.02.051. Epub 2009 May 4.